Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 4Phase 2 1

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 6Other solid neoplasm 4Gastrointestinal 2

Conditions

Solid Tumor, Adult 1Solid Tumor 1Pancreatic Neoplasms 1Mesothelioma 1KRAS p.G12C Mutant Advanced Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 41Injections 39toripalimab 23Nivolumab 22Cisplatin 19Pemetrexed 18Carboplatin 18Cyclophosphamide 17Paclitaxel 14Bevacizumab 14fludarabine 12Gemcitabine 11tislelizumab 10Ipilimumab 10spartalizumab 9Irinotecan 9atezolizumab 8Docetaxel 8Oxaliplatin 7Leucovorin 7Fluorouracil 7Capecitabine 6sintilimab 5Interleukin-2 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 4sotorasib 4pazopanib 4palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × sotorasib × Other solid neoplasm × Clear all
NCT07563738 2026-05-04

TEADCO

Orion Corporation, Orion Pharma

Phase 1/2 Recruiting
229 enrolled
GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Allist Pharmaceuticals, Inc.

Phase 1/2 Completed
58 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT04092673 2024-05-21

Zotatifin

Effector Therapeutics

Phase 1/2 Unknown
30 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡